NLA 2014 Scientific Sessions: Placing the Focus on Statin Intolerance

May 19, 2014
Roger Newton, PhD, FAHA
Executive Chairman and Chief Scientific Officer
Marianne Andreach
Vice President, Strategic Marketing & Product Planning

As members of the Esperion team developing ETC-1002—a unique, first-in-class, orally available, once-daily small molecule designed to lower low density lipoprotein cholesterol (LDL-C) levels, particularly in individuals with hypercholesterolemia who are intolerant to statins—we are excited any time there is a specific emphasis on, or a new development in, this underserved patient population. In the… Read More